Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Primary Immunodeficiency
How do you approach the use of immunosuppressive therapy in patients with rheumatoid arthritis and underlying immunodeficiency, such as IgA deficiency?
Patient has had multiple episodes of cellulitis. Is on treatment with methotrexate for RA
Related Questions
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
How do you handle medication refills for patients on traditional DMARDs who are lost to follow-up?
Does the pattern on chest CT help determine which patients with RA-ILD will respond to immunosuppression?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?
What is your approach to diagnosing and managing methotrexate-induced alopecia?
How do you approach management of a patient with multiple lung nodules and low titer +CCP but no active joint symptoms suggestive of RA?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?